Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

endocrine · Mechanism Report

Do the ovaries continue to contribute meaningfully to circulating testosterone across midlife?

The ovaries remain an active source of androgens through midlife, and declining ovarian function reduces overall androgen availability.

SupportedJune 19, 20268 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

In women, the ovaries contribute meaningfully to circulating testosterone across midlife, so declining ovarian function can reduce overall androgen availability.

laying out figure…
All 4 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

This claim states that ovarian steroidogenesis continues into midlife and supplies a substantial portion of circulating testosterone, so ovarian decline lowers the total androgen pool. The mechanism framing highlights both reduced ovarian androgen output and parallel adrenal involution as combined drivers of decreased overall androgen availability with aging.

Verified conclusion

The ovaries remain a physiologically active source of androgens throughout a woman’s life, including during and after the menopausal transition. While often overshadowed by the precipitous decline in estrogen, the transition through midlife involves significant shifts in the availability and source of circulating testosterone.

Clinical and physiological evidence

Research confirms that the ovaries contribute significantly to the female androgen pool, particularly during the reproductive years and midlife.

  • Production sources: In premenopausal women, approximately 25% of circulating testosterone is secreted directly by the ovaries (specifically via theca cells), 25% by the adrenal glands, and the remaining 50% is derived from the peripheral conversion of precursors like androstenedione.
  • Stability during transition: Data from the Study of Women's Health Across the Nation (SWAN) indicate that while estradiol levels collapse during the menopausal transition, total testosterone levels often remain relatively stable. This stability results in a state of "relative androgen excess," as the ratio of testosterone to estradiol increases significantly.
  • The postmenopausal ovary: The ovary does not become steroidogenically null after menopause. Longitudinal studies show that women who undergo bilateral oophorectomy (surgical removal of ovaries) experience a significantly sharper drop in circulating testosterone (roughly 40-50%) compared to women undergoing natural menopause, confirming that the postmenopausal ovary continues to contribute to the androgen pool.

Mechanistic explanations

The reduction in androgen availability during midlife is a dual process involving both ovarian aging and adrenal involution.

  • Ovarian shift: As ovarian follicles deplete, the primary site of steroidogenesis shifts. However, the ovarian stroma remains capable of producing androgens in response to elevated luteinizing hormone (LH) levels, which characterize the postmenopausal state.
  • Adrenal contribution: Parallel to declining ovarian function, the adrenal glands undergo age-related changes. The adrenal zona reticularis experiences gradual involution, leading to a steady decline in the secretion of dehydroepiandrosterone (DHEA) and DHEAS. Because these are primary precursors for peripheral testosterone conversion, their decline further reduces overall androgen availability.

Bottom line

The ovaries are a primary source of testosterone in midlife, contributing roughly one-third of direct secretion. While total testosterone levels may appear stable relative to the sharp drop in estrogen, the functional decline of the ovaries and the age-related reduction in adrenal precursors together reduce the total pool of available androgens as women age.

References

  1. Practical Approach to Hyperandrogenism in Women. — pmc.ncbi.nlm.nih.gov ↗
  2. SAT-022 Adrenal Androgen Production Is Maintained While Ovarian Estrogens Fall Following the Final Menstrual Period in the Study of Women’s Health Across the Nation (SWAN) — academic.oup.com ↗
  3. Steroid hormone levels in postmenopausal hysterectomised women with and without ovarian conservation: the continuous endocrine function of the ovaries — tandfonline.com ↗
  4. From adrenarche to aging of adrenal zona reticularis: precocious female adrenopause onset — ec.bioscientifica.com ↗
  5. From adrenarche to aging of adrenal zona reticularis: precocious female adrenopause onset — pmc.ncbi.nlm.nih.gov ↗
  6. Increasing the Testosterone Secretion From the Adrenal Glands in Male Transgenders Using Magnetic Nanoparticles — ajmb.umsha.ac.ir ↗
  7. Involvement of androgens in ovarian health and disease. — pmc.ncbi.nlm.nih.gov ↗
  8. Adrenopause – does it really exist? — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesCan obstructive sleep apnea lower testosterone in men?→Plausible5 sourcesDoes a non-elevated LH with low testosterone suggest secondary hypogonadism?→